Skip to main content
Back to General Atlantic

General Atlantic's Therapeutics Portfolio

Browse 8 Therapeutics companies funded by General Atlantic. See funding amounts, founder contacts, and investment details.

Therapeutics Companies
8
Total Funding in Therapeutics
$1.1B

Therapeutics Portfolio Companies (8)

Export
BiopharmaBiotechnologyTherapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.

Boston, United States
March 2026
$15.0M
Grant

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyHealth CareTherapeutics

Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.

Belmont, United States
December 2024
$50.4M
Venture - Series Unknown

Founder Contacts

19,000+ verified contacts

Health CareMedicalmHealthPersonal HealthTherapeutics

Vida Health is a virtual care platform that provides health coaching from experienced health care providers and medical institutions.

San Francisco, United States
November 2023
$28.5M
Venture - Series Unknown

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceTherapeutics

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

San Francisco, United States
October 2025
$250.0M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalOncologyTherapeutics

Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies.

Suzhou, China
July 2025
$25.0M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyPharmaceuticalTherapeutics

Ocumension Therapeutics is a pharmaceutical platform dedicated to identifying, developing, and commercializing ophthalmic therapies.

Shanghai, China
August 2024
$164.3M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyLife ScienceTherapeutics

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Cambridge, United States
March 2024
$366.9M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyPharmaceuticalTherapeutics

CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.

Cincinnati, United States
August 2022
$225.0M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

Explore General Atlantic's Full Portfolio

View all companies funded by General Atlantic across every industry and funding stage.

View Full General Atlantic Portfolio